Connection

Dariusz Pytel to Imatinib Mesylate

Back to Details
This is a "connection" page, showing publications Dariusz Pytel has written about Imatinib Mesylate.
Dariusz Pytel
Connection Strength
0.118
Imatinib Mesylate
  1. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance. Comp Biochem Physiol C Toxicol Pharmacol. 2006 Sep; 144(1):85-92.
    View in: PubMed
    Score: 0.068
  2. Imatinib (STI571) inhibits DNA repair in human leukemia oncogenic tyrosine kinase-expressing cells. Z Naturforsch C J Biosci. 2006 Nov-Dec; 61(11-12):896-902.
    View in: PubMed
    Score: 0.018
  3. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Mutat Res. 2006 Jan 31; 603(1):74-82.
    View in: PubMed
    Score: 0.017
  4. [Tyrosine kinases. New target of anticancer therapy]. Postepy Biochem. 2005; 51(3):251-60.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.